The Net Margin of Emergent BioSolutions Inc. (EBS) is
7.08%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
7.08%
|
| 2024-12-31 |
-18.26%
|
| 2023-12-31 |
-72.48%
|
| 2022-12-31 |
-18.88%
|
| 2021-12-31 |
12.24%
|
| 2020-12-31 |
19.62%
|
| 2019-12-31 |
4.93%
|
| 2018-12-31 |
8.01%
|
| 2017-12-31 |
14.73%
|
| 2016-12-31 |
10.60%
|
| Ticker |
Name |
Value |
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
2.23%
|
|
UTHR
|
United Therapeutics Corporation
|
41.94%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
-32.45%
|
|
ALKS
|
Alkermes Plc
|
16.37%
|
|
BHVN
|
Biohaven Ltd.
|
-1205.09%
|
|
BPMC
|
Blueprint Medicines Corp
|
-13.19%
|
|
FGEN
|
FibroGen Inc
|
-160.63%
|
|
IRWD
|
Ironwood Pharmaceuticals, Inc.
|
8.11%
|
|
LGND
|
Ligand Pharmaceuticals Incorporated
|
46.42%
|
|
CCXI
|
Churchill Capital Corp XI
|
-408.87%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
22.69%
|
|
RVMD
|
Revolution Medicines, Inc.
|
-3768.28%
|
|
FOLD
|
Amicus Therapeutics Inc
|
-4.27%
|
|
GBT
|
Global Blood Therapeutics Inc
|
-155.63%
|
|
LEGN
|
Legend Biotech Corporation
|
-28.85%
|
|
TPTX
|
Turning Point Therapeutics Inc
|
-767.30%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
-40.41%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
-148.38%
|
|
BLUE
|
Genetix Biotherapeutics Inc
|
-287.23%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
-609.85%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
-134.73%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
-1170863.70%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
-1141542.60%
|
|
DRNA
|
Dicerna Pharmaceuticals Inc
|
-68.59%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
-1800.58%
|